Syphilis is a sexually transmitted disease caused by infection spread by a bacteria called Spirochetal Bacterium. There are a number of signs and symptoms of syphilis including skin lesions on areas like the penis, vagina, and the rectum.
Syphilis has traditionally been treated with parenteral penicillin administered intramuscularly or intravenously. Because oral penicillin is not very effective in the treatment of syphilis, the signs and symptoms of syphilis have been controlled with the help of a number of medical breakthroughs. Some of these new treatments of syphilis are mentioned below.
- Benzathene Penicillin G: This drug regimen is highly effective for adults suffering from early latent syphilis. Almost 2.4 million units can be administered in a single intramuscular injection. Benzathene penicillin G is considered very efficacious in curing symptoms of syphilis.
- Benzathine Penicillin G: This is another new treatment method which has been approved for use by the FDA. It is used to treat the symptoms of late latent syphilis in adults with latent syphilis of unknown duration, or tertiary syphilis. This can also be administered in the quantity of 2.4 million units in a single intramuscular injection.
- Benzathin Penicillin G: A total of 7.2 million units of this penicillin derivative can be administered in three intramuscular doses to cure adults of neurosyphilis, or syphilitic eye disease; each at a week’s interval. Highly efficacious, benzathin penicillin G is one of the newest drugs that have been approved by the FDA for the treatment of syphilis.
- Aqueous Crystalline Penicillin G: 18 to 24 million units of this medicine can be administered per day. This is one of the new alternative treatment regimens for adults suffering from neurosyphilis or syphilitic eye disease.
- Procaine Penicillin: This can also be administered once a day, injecting 2.4 million units.
: This is the only new oral therapy that has been effective in treating syphilis, and it must be ingested four times a day for about 10 to14 days.
© Newsmax. All rights reserved.